The second‐generation curcumin analogue RL71 elicits G2 / M cell cycle arrest and apoptosis in canine osteosarcoma cells
Veterinary and Comparative Oncology · 2023
DOI: 10.1111/vco.12922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Barnaby Kelly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Curcumin, Dog Diseases, Osteosarcoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Otago.
Abstract (Originalsprache)
Canine osteosarcoma is an aggressive cancer, comprising 85% of canine bone neoplasms. Current treatment practices of surgery and chemotherapy increase 1‐year survival by only 45%. The curcumin analogue RL71, has demonstrated potent in vitro and in vivo efficacy in several models of human breast cancer through increased apoptosis and cell cycle arrest. Thus, the present study aimed to investigate efficacy of curcumin analogues in two canine osteosarcoma cell lines. Osteosarcoma cell viability was assessed using the sulforhodamine B assay and mechanisms of action were determined by analysing the levels of cell cycle and apoptotic regulatory proteins via Western blotting. Further evidence was obtained using flow cytometry to detect cell cycle distribution and the number of apoptotic cells. RL71 was the most potent curcumin analogue with EC 50 values of 0.64 ± 0.04 and 0.38 ± 0.009 μM ( n = 3) in D‐17 (commercial) and Gracie canine osteosarcoma cells, respectively. RL71 significantly increased the ratio of cleaved‐caspase 3 to pro‐caspase 3 and the level of apoptotic cells at the 2× and 5× EC 50 concentration ( p < 0.001, n = 3). Furthermore, at the same concentration, RL71 significantly increased the number of cells in the G2/M phase. In conclusion, RL71 has potent cytotoxic activity in canine osteosarcoma cells triggering G2/M arrest and apoptosis at concentrations achievable in vivo. Future research should further investigate molecular mechanisms for these changes in other canine osteosarcoma cell lines prior to in vivo investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
- Flint Animal Cancer Center, Colorado State University, Ft. Collins, Colorado, USA.
Förderung
- University of Otago
Zitieren
APA
Kelly, B., Thamm, D., & Rosengren, R. J. (2023). The second‐generation curcumin analogue RL71 elicits G2 / M cell cycle arrest and apoptosis in canine osteosarcoma cells. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12922
Vancouver
Kelly B, Thamm D, Rosengren RJ. The second‐generation curcumin analogue RL71 elicits G2 / M cell cycle arrest and apoptosis in canine osteosarcoma cells. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12922
BibTeX
@article{Kelly2023,
author = {Kelly, Barnaby and Thamm, Douglas and Rosengren, Rhonda J},
title = {The second‐generation curcumin analogue RL71 elicits G2 / M cell cycle arrest and apoptosis in canine osteosarcoma cells},
journal = {Veterinary and Comparative Oncology},
year = {2023},
doi = {10.1111/vco.12922}
}
EUVIMED